Bei Akademie registrieren
Inhibrx Biosciences stock, CTOS

Inhibrx Biosciences stock faces a busy clinical-data calendar

Published on 11/05/2026 at 03:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Inhibrx Biosciences stock has a full slate of oncology presentations ahead. The company will present new ozekibart analyses at CTOS in November.

Upcoming oncology presentations

  • Inhibrx plans scientific presentations covering ozekibart and its oncology pipeline at the CTOS meeting.
  • The conference schedule gives investors a near-term update point for clinical development progress.
Inhibrx Biosciences stock, CTOS, ozekibart, INBRX-109, oncology, clinical trials, Illustration mit AI erstellt.
Inhibrx Biosciences stock, CTOS, ozekibart, INBRX-109, oncology, clinical trials, Illustration mit AI erstellt.

Inhibrx Biosciences announced on October 13 that it would participate in several scientific conferences, including the upcoming Connective Tissue Oncology Society meeting in Seoul. The company's investor information lists oral and poster presentations for November 19 and 20.

CTOS sets the next milestone

Inhibrx plans to present updated progression-free survival and subgroup findings from the randomized Phase 2 ChonDRAgon study of ozekibart, also known as INBRX-109, in conventional chondrosarcoma. A separate presentation will cover the drug candidate in combination with irinotecan and temozolomide for adolescents and adults with Ewing sarcoma.

The schedule gives investors a near-term clinical update point. The planned presentations concern efficacy and treatment combinations, areas that can shape expectations for the development path of an oncology pipeline.

Clinical-stage biotech focus

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutic candidates. Its investor materials describe an adaptable platform and highlight programs including ozekibart and ordastobart, also known as INBRX-106. The company is focused on clinical development rather than a broad portfolio of marketed medicines, placing its progress around trial results and scientific disclosures.

Inhibrx Biosciences at a glance

  • Company: Inhibrx Biosciences, Inc.
  • Ticker: INBX
  • Exchange: Nasdaq Global Market
  • Business: Clinical-stage biopharmaceutical development
  • Headquarters: La Jolla, California, United States

US equity markets provide the broader backdrop for biotechnology shares; follow the S&P 500 for the wider market context.

Further company announcements and presentation materials are available through the Inhibrx investor page.

Disclaimer...
en | boerse | 70460463 |